ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1211

Adult Autoinflammatory Phenotypes Associated With Heterozygous MEFV Mutations: A Continuum of Familial Mediterranean Fever?

Qingping Yao, Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Familial Mediterranean fever, Fever, Genetic Biomarkers, genomics and inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases I: Autoinflammatory Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Familial Mediterranean fever (FMF) is traditionally regarded as an autosomal recessive disease characterized by periodic fever, serositis, erysipelas-like erythema and good response to colchicine. The aim of this study was to analyze a cohort of adult patients with autoinflammatory phenotypes and heterozygous MEFV mutations.

Methods:

A group of 8 patients were cared for by the author between 2011 and 2012, and retrospectively studied for their clinical phenotypes. Genetic testing for MEFV mutations was performed (GeneDx, MD).

Results:

Eight patients consisted of 5 women, 3 men, 7 whites and 1 Arab.  The mean age at disease onset was 30.5 years with only 1 patient with early-onset. All but the early-onset patient denied any family history of periodic fever syndrome. Of the 8 patients, there were 7 patients with arthritis, 6 intermittent fever, 4 abdominal pain, 3 chest pain, and 3  non erysipelas-like rash. None of the patients had proteinuria.  All patients carried a single copy of heterozygous MEFV mutations, including V726A (2), K695R (2), M694V (1), E148Q (1), new mutations R329H (1) and G136V (1) (Table 1). In a study of 18 FMF early-onset patients with a single MEFV mutation, most patients reportedly presented with fever and abdominal pain with prompt response to colchicine therapy. In the current adult cohort, most patients had fever and inflammatory arthritis with poor response to colchicine. Instead, 3 of the 8 patients required treatment with prednisone in 2 cases and etanercept in 1 (R329H).

Conclusion:

This study supports the presence of the clinical entity associated with a single heterozygous MEFV mutation.  The adult-onset entity may be distinct from classic FMF and early-onset form. Future study to differentiate between the adult- and early-onset forms will be needed.


Disclosure:

Q. Yao,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adult-autoinflammatory-phenotypes-associated-with-heterozygous-mefv-mutations-a-continuum-of-familial-mediterranean-fever/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology